BBDF-101

BBDF-101 is an investigational, proprietary **combination therapy** for juvenile Batten disease (CLN3 neuronal ceroid lipofuscinosis) composed of the approved drugs **trehalose** and **miglustat**, designed to synergistically enhance lysosomal clearance of toxic storage material and slow neurodegeneration by activating the transcription factor EB (TFEB) pathway and modulating glycosphingolipid metabolism.[1][2][3][5][7][9] Developed jointly by Theranexus (now THX Pharma) and the Beyond Batten Disease Foundation under an exclusive global license, BBDF-101 received orphan drug designation in the US and EU and rare pediatric disease designation in the US for neuronal ceroid lipofuscinosis, and entered Phase I/II clinical development in CLN3 disease following FDA IND clearance in 2021.[1][2][5][7][9][13][15] In 2023–2024, based on preclinical and clinical data suggesting superior performance of miglustat alone, the partners transitioned development from the trehalose+miglustat combination to a new miglustat-only formulation branded as Batten-1, making BBDF-101 an earlier-stage combination predecessor rather than the current lead candidate.[3][4]